Materialise N.V. (NASDAQ:MTLS) is a leading company in the 3D printing solutions sector, offering innovative software and services across healthcare, automotive, and aerospace industries. Headquartered in Belgium, Materialise operates on a global scale and faces competition from companies like Proto Labs, Inc. (PRLB), Veracyte, Inc. (VCYT), Stratasys Ltd. (SSYS), 2U, Inc. (TWOU), and Twist Bioscience Corporation (TWST).
In assessing Materialise's financial health, the Return on Invested Capital (ROIC) is a crucial metric. The company's ROIC stands at 2.41%, significantly lower than its Weighted Average Cost of Capital (WACC) of 10.32%. This discrepancy suggests that Materialise is not generating sufficient returns to cover its cost of capital, raising concerns among investors about its capital efficiency.
Comparatively, Proto Labs, Inc. (PRLB) reports a ROIC of 1.62% and a WACC of 10.07%, leading to a ROIC to WACC ratio of 0.16. Despite PRLB's ROIC also falling below its WACC, it demonstrates better capital management than its peers. On the other hand, Veracyte, Inc. (VCYT) and Stratasys Ltd. (SSYS) have lower ROICs of 0.99% and -6.64%, respectively, with corresponding WACCs that underscore significant challenges in surpassing their cost of capital.
Furthermore, 2U, Inc. (TWOU) and Twist Bioscience Corporation (TWST) exhibit negative ROICs of -62.87% and -24.84%, with WACCs of 7.38% and 14.41%. Their negative ROIC to WACC ratios highlight severe inefficiencies in capital utilization. Despite these challenges, Materialise maintains a relatively higher ROIC to WACC ratio compared to its peers, indicating a more efficient use of capital in the competitive 3D printing industry.
